New developments in the treatment of chronic lymphocytic leukemia: role of obinutuzumab

Obinutuzumab is a novel glycoengineered type II anti-CD20 monoclonal antibody with a higher affinity for CD20 epitope, enhanced antibody-dependent cellular cytotoxicity and direct cell death, leading to superior cytotoxicity compared with rituximab. The approval of obinutuzumab by US Food and Drug A...

Descripción completa

Detalles Bibliográficos
Autor principal: Shah, Arpita
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4524526/
https://www.ncbi.nlm.nih.gov/pubmed/26251607
http://dx.doi.org/10.2147/TCRM.S71839

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4524526/
https://www.ncbi.nlm.nih.gov/pubmed/26251607
http://dx.doi.org/10.2147/TCRM.S71839

Ejemplares similares